Evidence map›Paper›PMID 20167668›Full record

Trial reportJournal of applied physiology (Bethesda, Md. : 1985)2010

Exercise and the metabolic syndrome with weight regain.

Tom R Thomas, Shana O Warner, Kevin C Dellsperger, Pamela S Hinton, Adam T Whaley-Connell, R Scott Rector, Ying Liu, Melissa A Linden, Anand Chockalingam, John P Thyfault and 3 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of applied physiology (Bethesda, Md. : 1985), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04122716 (Synergy Effect of the Appetite Hormone GLP-1), which is not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04122716 phase4unknown statusstarted 2016, after this paper: background citation

Synergy Effect of the Appetite Hormone GLP-1 (LiragluTide) and Exercise on Maintenance of Weight Loss and Health After a Low Calorie Diet - the S-LiTE Randomized Trial

Ran2016Enrolled215Registered outcomes28Posted comparisons0ConditionsObesityArmsExercise, liraglutide
Open the trial in the graph
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Walking for hypertension.The Cochrane database of systematic reviews · 2021
    Pooled it
  2. Trial
  3. Simvastatin impairs exercise training adaptations.Journal of the American College of Cardiology · 2013 · on this map
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Increasing the health span: unique role for exercise.Journal of applied physiology (Bethesda, Md. : 1985) · 2025
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Influence of Physical Activity on the Regulation of Disease of Elderly Persons with Metabolic Syndrome.International journal of environmental research and public health · 2021
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Tom R ThomasDepartment of Nutrition and Exercise Physiology, University of Missouri, Columbia, MO 65211, USA. thomastr@missouri.edu
Shana O Warner
Kevin C Dellsperger
Pamela S Hinton
Adam T Whaley-Connell
R Scott Rector
Ying Liu
Melissa A Linden
Anand Chockalingam
John P Thyfault
David R Huyette
Ze Wang
Richard H Cox
Canadian Society for Exercise Physiology · CAHarry S. Truman Memorial Veterans' Hospital · USUniversity of Missouri · US

Funding

Exercise &Health: Integration from Molecule to PatientT32AR048523 · NIAMS · UNIVERSITY OF MISSOURI-COLUMBIA · PI TERJUNG, RONALD L · 2003 to 2013
$2.5M
Exercise and the Metabolic Syndrome with Weight RegainR01DK067036 · NIDDK · UNIVERSITY OF MISSOURI-COLUMBIA · PI THOMAS, TOM R · 2006 to 2009
$1.2M
NIAMS NIH HHS T32-AR-048523NIDDK NIH HHS R01-DK-067036
6 · The paper itself

Abstract

Weight loss improves metabolic syndrome (MetS) factors, but risk may return with weight regain. This study was designed to determine if exercise training can maintain improvements in MetS risk factors during weight regain. In a randomized control trial,102 overweight or obese (body mass index 25.0-39.9 kg/m(2)) men and women (age 21-52 yr), with characteristics of the MetS, lost 10% of body weight with supervised walking/jogging at 60% of maximal oxygen consumption (Vo(2 max)) (-400 kcal/session), 5 days/wk, and caloric restriction (-600 kcal/day) over a 4- to 6-mo period. After weight loss, 77 remaining subjects underwent programmed weight regain (+50% of lost weight) for 4-6 mo with random assignment to two groups: no exercise (NoEX) or continued supervised exercise (EX). Blood pressure, regional fat, glucose homeostasis, lipids, and inflammatory markers were assessed at baseline, post-weight loss, and post-weight regain. Groups were compared by two-way repeated-measures ANOVA on the 67 subjects. After weight loss (9.7 +/- 0.2% of body weight), significant (P < 0.05) improvements were observed in almost all parameters assessed. Following weight regain (54.4 +/- 1.6% of lost weight), the NoEX group exhibited deterioration in most metabolic markers, while the EX group maintained improvements in Vo(2 max), blood pressures, glucose homeostasis, high- and low-density lipoprotein cholesterol (HDL-C and LDL-C), oxidized LDL, and other markers of inflammation, but did not maintain improvements in triglyceride and cholesterol concentrations or abdominal fat. Results of this design of controlled human weight regain suggest that aerobic exercise can counter the detrimental effects of partial weight regain on many markers of disease risk.

Indexed as

Abdominal FatAdultBlood GlucoseBlood PressureBody WeightCaloric RestrictionCholesterol, HDLCholesterol, LDLExerciseFemaleHumansLipidsMaleMetabolic SyndromeMiddle AgedObesityBlood GlucoseCholesterol, HDLCholesterol, LDLLipids

Identifiers

PMID20167668
PMCPMC2904200
OpenAlexW2058028409

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.